Picard Medical (NYSE: PMI) presents Emperor Total Artificial Heart in vitro data

Rhea-AI Filing Summary

Picard Medical, Inc. reported that its Engineering Project Manager, Duffy Elmer, presented in vitro data on the company’s Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support in Vienna, Austria. The presentation highlights ongoing development work on the Emperor Total Artificial Heart, a key technology in the company’s portfolio.

The company made available an abstract of the Emperor Total Artificial Heart and the slide deck used in the presentation as exhibits to this report. These materials are furnished, not filed, which means they are provided for information purposes and are not subject to the liability provisions that apply to formal filed reports.

false 0002030617 0002030617 2025-12-04 2025-12-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 4, 2025

 2025-11-25

Picard Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42801		86-3212894
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1992 E Silverlake Tucson AZ, 85713

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (520) 545-1234

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		PMI		The NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On December 4, 2025, Duffy Elmer, Engineering Project Manager of Picard Medical, Inc. (the “Company”) presented in vitro data on the Emperor Total Artificial Heart at the 31^st Annual Meeting of the International Society for Mechanical Circulatory Support in Vienna, Austria. A copy of the abstract that Mr. Elmer presented on is furnished as Exhibit 99.1 and the slide deck utilized during his presentation is furnished as Exhibit 99.2, each of which is incorporated by reference herein.

The information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
99.1		Abstract of The Emperor Total Artificial Heart, dated December 4, 2025.
99.2		Presentation Slide Deck, dated December 4, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Picard Medical, Inc.
By:	/s/ Patrick NJ Schnegelsberg
	Name:	Patrick NJ Schnegelsberg
	Title:	Chief Executive Officer

Dated: December 4, 2025

2

FAQ

What did Picard Medical (PMI) announce in this 8-K filing?

Picard Medical disclosed that Engineering Project Manager Duffy Elmer presented in vitro data on the Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support in Vienna, Austria, and furnished the related abstract and slide deck as exhibits.

What is the Emperor Total Artificial Heart mentioned by Picard Medical (PMI)?

The Emperor Total Artificial Heart is Picard Medical’s artificial heart technology. In this report, the company notes that in vitro data on this device was presented at an international mechanical circulatory support conference, indicating ongoing technical and scientific work on the product.

Are the materials about the Emperor Total Artificial Heart considered filed with the SEC for Picard Medical (PMI)?

No. Picard Medical states that the information in this report and the related exhibits are furnished, not filed, under the Securities Exchange Act of 1934. As a result, they are not subject to the same liability provisions as information formally filed with the SEC.

What exhibits did Picard Medical (PMI) include with this 8-K?

Picard Medical included three exhibits: Exhibit 99.1, the abstract titled The Emperor Total Artificial Heart dated December 4, 2025; Exhibit 99.2, the presentation slide deck dated December 4, 2025; and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed this Picard Medical (PMI) 8-K and in what capacity?

The report was signed on behalf of Picard Medical, Inc. by Patrick NJ Schnegelsberg, who is identified as the company’s Chief Executive Officer.

Does this Picard Medical (PMI) 8-K report any financial results or major transactions?

This report focuses on the presentation of in vitro data for the Emperor Total Artificial Heart and the furnishing of related materials. It does not describe financial results or major corporate transactions in the disclosed text.